Aciryl

Quick links to important sections

Aciryl

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aciryl

Quick Facts
Active Ingredient Pregabalin
Form Hard Capsules, Oral Solution, Extended-Release Tablets
Pharmacological Class Anticonvulsant, Gabapentinoid, Analgesic
Common Use Management of nerve-related pain and seizures
Origin Synthetic Compound (Structural derivative of GABA)

Aciryl: Definition, Active Ingredient, and Pharmacological Class

Aciryl is a prescription-only synthetic pharmaceutical product primarily classified as an anticonvulsant and analgesic, belonging to the gabapentinoid class. Its function centers on modulating nerve signaling within the central nervous system. The active ingredient in Aciryl is Pregabalin, a chemical entity structurally related to gamma-aminobutyric acid (GABA). Pregabalin is utilized in the treatment of nerve pain, epilepsy, and generalized anxiety disorder. This classification as a gabapentinoid signifies its core capacity to stabilize and dampen excessive electrical activity in the nervous system, distinguishing it from medications that act on different receptor targets.


Composition, Origin, and Available Forms

Aciryl is a single active ingredient product that utilizes Pregabalin as its sole therapeutic substance, designed for oral administration. The medicine is of synthetic origin and is supplied in several distinct oral dosage forms, including standard hard capsules, an oral solution suitable for patients who prefer liquid formulations, and sometimes extended-release tablets. The inclusion of the extended-release tablet form is clinically recognized for allowing less frequent daily dosing compared to immediate-release variants.


General Purpose: Calming Overactive Nerve Signals

The general therapeutic purpose of Aciryl is to stabilize neurological function and mitigate the transmission of abnormal nerve-mediated signals. Aciryl achieves this by binding to the alpha2-delta (alpha2delta) subunit of voltage-gated calcium channels on nerve terminals, which results in the reduced release of key excitatory neurotransmitters. The medicine's core goal is to dampen uncontrolled electrical firing and mitigate the severity of abnormal nerve-mediated signals, thereby providing relief by normalizing excessive neurological activity associated with various underlying chronic conditions.

Regulatory References

  1. EMA Public Assessment Report (EPAR) for Lyrica (Pregabalin)
  2. EPAR for Lyrica (Pregabalin)

What side effects are possible with Aciryl?

Official Safety Profile and Adverse Reactions

The safety profile of Aciryl (Pregabalin) is structured by official regulatory frequency classifications and System-Organ Classes (SOCs). The most commonly documented adverse reactions, classified as Very Common (1 in 10), include Dizziness and Somnolence (sleepiness). Reactions classified as Common (1 in 100) encompass Peripheral edema, Weight gain, Blurred vision, Ataxia (lack of coordination), Confusion, and Euphoric mood.

Key safety warnings highlighted in regulatory documents concern serious, albeit rare, adverse reactions.

Serious Adverse Reactions

Category Description
Hypersensitivity Risk of Angioedema (swelling of the face, mouth, tongue, or throat)
Psychiatric Documented risk of Suicidal Behavior and Ideation
Dermatological Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
Respiratory Severe Respiratory Depression, particularly when co-administered with CNS depressants

Special Safety Considerations

The regulatory profile specifies constraints for certain patient groups. Individuals with Renal Impairment require particular attention, as the medicine is primarily eliminated through the kidneys, and dose adjustments are officially necessary. Older Adults may have an increased risk of falls due to associated dizziness and somnolence. The official label also notes the risk of Congestive heart failure, primarily observed in elderly patients with pre-existing cardiovascular conditions.

Time-Related Safety Patterns

Adverse reactions are often dose-dependent, with a higher incidence noted at maximal doses. Regulatory safety constraints mandate that treatment discontinuation must be gradual (over a minimum of 1 week) to mitigate the risk of seizures and withdrawal symptoms such as insomnia and headache.

Overdose and Emergency Response

Aciryl Overdose and When to Seek Help

This information is based strictly on the official overdose sections of government regulatory documents.


Documented Overdose Profile

Official regulatory information describes potential manifestations of an Aciryl overdose, which may include signs such as excessive somnolence, bradycardia, and hypotension.

Laboratory findings associated with overdosage, such as elevated liver enzymes, have been noted. The official labeling emphasizes the potential for serious delayed sequelae, requiring an extended observation period and caution for certain populations, such as those with pre-existing renal impairment.


Required Emergency Action

Action Domain Regulatory Requirement (Official Statement)
Immediate Contact Immediately contact a medical toxicologist or the Poison Help Line for management guidance.
Urgent Care Seek urgent medical attention and report to an emergency room for any suspected overdose exposure.
Management Measures Management must prioritize the support of vital functions and adherence to specific decontamination procedures, such as the use of activated charcoal.

The regulatory basis for the overdose profile defines a clear path of Mandated Emergency Action to mitigate the established clinical risks. This approach ensures consistent and immediate steps are taken following any suspected overdosage, focusing entirely on emergency stabilization and defined supportive care.

Therapeutic Uses of Aciryl

Quick Facts: Therapeutic Domains

  • Management of certain types of neuropathic pain.
  • Used as an adjunctive treatment for partial-onset seizures.
  • Supports the treatment of generalized anxiety disorder (GAD).

Aciryl is an established prescription medication utilized in adults for the management of specific conditions.

Neuropathic Pain

The medication is used to address pain resulting from nerve damage, referred to as neuropathic pain. This includes peripheral neuropathic pain associated with conditions such as diabetic peripheral neuropathy and postherpetic neuralgia (shingles pain). It is also approved for the management of central neuropathic pain, such as that linked to spinal cord injury.

Epilepsy

Aciryl serves as an adjunctive therapy for the treatment of partial-onset seizures in adults. This means it is typically prescribed in addition to existing epilepsy treatments when current therapy is not sufficiently controlling the condition. The medication may contribute to a reduction in seizure frequency.

Generalized Anxiety Disorder (GAD)

It is also indicated for the long-term management of Generalized Anxiety Disorder (GAD). This treatment is intended to help manage symptoms of prolonged, excessive worry, and anxiety that can be difficult to control.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Aciryl (Pregabalin) — Official Regulatory Information

Eligibility Scope

Classification Population Group Regulatory Status
Allowed Adults (ge 18 years) Approved for all established indications.
Allowed (Conditional) Pediatric Patients (ge 1 month) Approved as adjunctive therapy for partial-onset seizures.
Not Recommended Pregnant/Breastfeeding Individuals Use is not recommended due to official warnings of potential risk.
Contraindicated Hypersensitivity Absolute contraindication to Pregabalin or its excipients.

Age-Related Eligibility Rules

  • Children and Adolescents (lt 18 years): Safety and efficacy are not established for non-seizure indications, such as pain.
  • Older Adults (Geriatric): Eligible for use, but may require a dose reduction due to likely decreased renal function.

Eligibility-Related Restrictions

  • Reduced Renal Function: Use is conditional and requires mandatory individual dose adjustment based on creatinine clearance.
  • Respiratory Compromise: Patients with compromised breathing function are designated as a higher-risk group due to the potential for severe respiratory depression.
  • Comorbidity History: Conditional use due to a documented potential for dependence and heightened risk in cardiovascular compromised patients.

Connection to the Overall Eligibility Profile

Official regulatory documents establish a strict framework by defining clear exclusions for hypersensitivity, making use conditional on renal function, and deeming it not recommended during pregnancy and lactation. This structure ensures eligibility is governed by physiological capacity and established age limitations, not solely by the patient's condition.

What should I know about interactions with other medicines?

The official interaction profile for Aciryl (Pregabalin) is primarily defined by pharmacodynamic effects and its negligible metabolic activity.

Pharmacodynamic Interactions

Co-administration with other Central Nervous System (CNS) depressants, including opioid medicines, benzodiazepines, and alcohol, carries a formally documented additive effect. This potentiation significantly increases the risk of severe sedation and respiratory depression according to regulatory warnings. Furthermore, co-administration with thiazolidinedione antidiabetic agents (e.g., pioglitazone) is officially associated with an increased frequency of peripheral edema and weight gain.

Pharmacokinetic Status

Aciryl is characterized by negligible metabolism in humans and does not inhibit or induce major liver enzymes, such as the CYP450 system. Consequently, regulatory labels state there are no clinically significant pharmacokinetic interactions expected with commonly co-administered antiepileptic drugs, including carbamazepine, valproic acid, and lamotrigine.

Special Interaction Constraints

Aciryl's systemic exposure is directly proportional to renal clearance. This established clearance constraint means that reduced renal function in populations such as the elderly results in increased drug levels, a factor noted in official prescribing information. The co-administration of alcohol is explicitly restricted due to the severe potentiation of CNS depressant effects. The Extended-Release formulation is subject to an official timing rule specifying administration after an evening meal to manage absorption kinetics.

Mechanism of Action

Modulation of Calcium Channel Activity

Aciryl acts within domains involving receptor-mediated signaling by binding specifically to the alpha-2-delta (alpha2delta) subunit of presynaptic voltage-gated calcium channels (VGCCs) in the central nervous system (CNS). This binding is essential to its mechanism and regulates the activity of neuronal signaling pathways in the CNS.


Regulation of Excitatory Neurotransmitter Release

The binding to the alpha2delta subunit initiates a mechanistic cascade that suppresses signaling sequences. Specifically, it reduces the depolarization-induced influx of calcium ions, which, in turn, decreases the release of several excitatory neurotransmitters such as glutamate and substance P. This affects systems where specific transmitters dominate, modulating processes driven by distinct signaling patterns.


️ Influencing Neuronal Signaling Thresholds

The overall pathway effect of reducing excitatory neurotransmitter release modifies the threshold for physiological responses. This leads to a more regulated state within targeted neural pathways, decreasing local mediator activity, and influencing the systemic adjustment of neuronal signaling.

Dosage and Administration Information

How to Use Aciryl: Administration Guidelines

This section outlines the instructions for use of Aciryl (e.g., Pregabalin), detailing the rules for administration, dosage, and scheduling.

Administration and Dosing

Aciryl is approved for oral administration. The medicine can be administered in several forms, including capsules, oral solution, and extended-release (CR) tablets, though administration specifics vary by form.

Administration Component Instruction
Route Oral
Frequency Typically 2 or 3 times per day, in divided doses.
Timing (Capsules/Solution) May be taken with or without food.
Timing (CR Tablets) Should be taken after an evening meal.

Dosage and Special Requirements

The initial daily dose is generally 150 mg/day, divided into the prescribed frequency. The dose may be increased after a minimum of one week based on the prescribed regimen, up to a maximum daily dose of 600 mg/day.

Special Conditions:

  • Renal Function: The instructions mandate that the dose must be significantly reduced if the patient has reduced kidney function (CLcr < 60 mL/min). Dosing is determined by specific formulas or tables.
  • Pediatric Use: For pediatric patients 4 years and older with certain conditions, dosing is based on the patient’s body weight in kilograms (kg). The maximum dose for this group must not exceed 600 mg/day.
  • Discontinuation: Treatment must not be stopped suddenly. The instructions require that the medicine be tapered gradually over a minimum period of one week to prevent acute reactions.

Procedural Summary

The established protocol defines a titration process (gradual increase) and taper (gradual decrease). It links the final dosage amount and frequency directly to individual factors, particularly renal clearance, ensuring use is standardized across all patient groups.

Recent Clinical Evidence

Research evidence / Overview of studies for Aciryl


Evidence for use in Neuropathic Pain associated with Diabetic Peripheral Neuropathy

Aciryl was studied for use in adults experiencing nerve-related discomfort linked to diabetic complications. The research exploring this condition primarily involved randomized controlled trials (RCTs). These studies typically tracked changes in patient-reported outcomes describing perceived discomfort over relatively short-term periods. The populations included adults with a diagnosis of diabetic peripheral neuropathy who were experiencing ongoing nerve pain. Studies reported measurements of how pain scores changed during the observation period. Some trials described patterns such as differences in the reported discomfort levels between groups that received Aciryl and those that received a placebo. Long-term effects are not fully established for this indication. Follow-up durations were limited in most of the existing research, meaning that how reported outcomes evolve over many months or years is not well characterized.


Evidence for use in Postherpetic Neuralgia

Aciryl was evaluated in studies focused on persistent nerve-related discomfort (Postherpetic Neuralgia) that can occur after a shingles infection. This research primarily involved RCTs examining symptom intensity or variability in adult populations. These trials typically monitored changes in outcomes related to physical discomfort over defined, short-to-medium-term time intervals. The studies reported measurements of changes in pain intensity, which was observed in some studies to shift over the trial period. Research describes how some patients tracked measured changes in pain-related daily functioning or activity level during the study period. Limited information for long-term outcomes is available, so it is still uncertain how the observed changes persist beyond the study duration.


Evidence for use as Adjunctive Therapy for Partial-Onset Seizures

Aciryl was studied for use alongside other seizure medications in people with partial-onset seizures. These studies involved populations including both adult and pediatric patients with this seizure type. The main outcomes measured included the frequency of seizures over the defined time intervals of the study. Research highlights changes measured during the study period regarding seizure frequency. Data for certain groups remain insufficient, particularly for some subgroups within the pediatric populations studied. Long-term outcomes are not fully established regarding the long-term patterns observed when Aciryl was studied as an add-on therapy.


What is Still Uncertain about Aciryl

A number of research gaps and limitations currently exist in the evidence base for Aciryl. Follow-up durations were limited across many of the conditions studied, meaning that long-term outcomes for patients remain uncertain. Sample sizes were modest in some key trials, and evidence quality varies across studies, contributing to findings that were mixed in certain areas. Comparative evidence is lacking to fully understand how the observed patterns compare to patterns seen with other available treatments. Overall, the existing studies provide limited insight into the full context of long-term use, and these knowledge gaps remain.

Key Studies & References

  1. Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia (NCT00830167)

Frequently Asked Questions (FAQ)

Common questions about Aciryl (FAQ)

Q: How quickly can someone expect to feel the effects of Aciryl?

A: Studies and official information indicate that for certain conditions, a noticeable improvement in patient-reported outcomes, such as pain scores, may begin as early as Week 1 compared to placebo. Individual responses to medication and symptom relief times can vary.

Q: Can Aciryl cause weight gain or loss?

A: Regulatory documents state that weight gain is a commonly reported side effect. While less common, weight loss has also been reported in official adverse reaction databases. Concerns about changes to weight should be discussed with a healthcare provider.

Q: How long after stopping Aciryl do the effects wear off?

A: The medicine has an approximate elimination half-life of 6.3 hours. Official instructions indicate that treatment should not be stopped suddenly, but instead be gradually tapered over a minimum period of one week to help prevent withdrawal symptoms and seizure risk.

Q: How long does a course of treatment with Aciryl usually last?

A: For chronic conditions like nerve pain and fibromyalgia, treatment is generally considered long-term. Regulatory guidelines recommend that the continued need for treatment should be reassessed regularly by a qualified healthcare professional.

Q: How is Aciryl processed by the liver?

A: According to official regulatory information, Aciryl is characterized by negligible metabolism in humans. This means the medicine is largely not broken down by the liver and is instead excreted mainly unchanged by the kidneys. Official label information indicates that dose adjustments are typically not required for patients with liver impairment.

Q: Is it normal to feel a mild headache after taking Aciryl?

A: Headache is listed as an uncommon adverse reaction in official product safety documents. Headache is also a symptom that may occur as part of a withdrawal process if the medicine is stopped without tapering.

Q: Is there a generic version of Aciryl available?

A: Yes. The active ingredient in Aciryl, Pregabalin, has been approved by regulatory bodies like the FDA for generic versions. These generic forms are available in various strengths and oral forms.

Q: Can Aciryl affect sleep patterns?

A: Yes, sleep-related effects are commonly reported. Somnolence (sleepiness) is listed as a very common side effect in official safety profiles. Other issues like insomnia and nightmares have also been reported, particularly when the medicine is being discontinued.

Q: Does Aciryl need to be taken with food?

A: This depends on the specific formulation being taken. Immediate-release capsules or oral solution may be taken with or without food. However, the extended-release tablets must be taken after an evening meal to manage absorption kinetics as per official instructions.

Q: Are there any natural supplements that are known to interact with Aciryl?

A: Official drug labels primarily detail interactions with other medications that slow down the central nervous system, such as alcohol and opioid medicines. No specific natural supplements are listed on the regulatory label as having a significant interaction.

Q: Has Aciryl been approved for use in children?

A: Aciryl is approved for use in pediatric patients (generally ages 4 and up) only as an add-on treatment for partial-onset seizures. Official information states that the safety and effectiveness of the medicine for pain-related conditions have not been established in children.

Q: Is Aciryl safe during pregnancy?

A: Use of Aciryl is not recommended during pregnancy due to potential risks observed in animal studies. Official documents often encourage enrollment in regulatory pregnancy registries for monitoring individuals who have taken the medicine while pregnant.

Q: Can people with liver or kidney problems use Aciryl?

A: Official guidance states that people with reduced kidney function often need a mandatory adjustment to the dose because the medicine is primarily cleared by the kidneys. Dosing is generally not affected by liver problems since the drug is minimally metabolized by the liver.

Q: Does Aciryl show up on standard drug tests?

A: Aciryl (Pregabalin) is classified as a controlled substance. While it is generally not detected on standard, basic drug screens, specific laboratory tests for Pregabalin are available and used for clinical monitoring purposes.

Q: Is it important to take Aciryl at the same time every day?

A: Yes. Since the immediate-release form is usually taken two or three times a day and the drug has a short half-life, maintaining a consistent daily dosing schedule helps keep the drug's level stable in the body. This consistency helps maintain stable drug levels, which supports the medicine working as intended.

Q: What is the shelf life of Aciryl once the bottle is opened?

A: The official product label provides an expiration date for the unopened medicine. However, some patient information leaflets instruct patients to use the oral solution within 90 days after initially opening the bottle.

Q: Does Aciryl interact with birth control pills?

A: Official studies indicate that there are no clinically significant interactions between Aciryl and common oral contraceptives, such as those containing ethinyl estradiol and levonorgestrel.

Q: How is Aciryl stored?

A: Aciryl should be stored at Controlled Room Temperature, which is between 20 C and 25 C. It is crucial to keep the container cap tightly closed and protect the medicine from excessive heat and moisture, meaning it should not be stored in places like a bathroom.

Q: Is the effectiveness of Aciryl reduced by alcohol consumption?

A: The regulatory label does not specifically state that alcohol reduces the effectiveness of the medicine. However, alcohol is strictly restricted because it significantly and potentially dangerously increases the central nervous system side effects, such as dizziness and severe drowsiness.

Q: Does smoking affect how Aciryl works?

A: Official drug interaction studies do not list nicotine or smoking as having a significant effect on how Aciryl is processed by the body. This is because the medicine is minimally metabolized by the liver enzymes that are typically affected by smoking.

Q: What does the patient information leaflet for Aciryl say about driving?

A: The official patient leaflet warns that Aciryl commonly causes side effects like dizziness and drowsiness. The leaflet states that people taking Aciryl should not drive or operate heavy machinery until they know how the medicine affects their ability to perform these tasks.

How should Aciryl be stored and disposed of?

Official Storage and Disposal Instructions

Storage Conditions

Aciryl (Pregabalin) capsules and oral solution must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with excursions permitted between 15 C and 30 C (59 F and 86 F). The medicine must be kept in the container it came in, with the cap tightly closed, and protected from excessive heat and moisture. Regulatory guidance specifically advises against storing it in high-moisture areas, such as a bathroom.

Child-Safety Storage

All forms of this medication must be stored strictly out of the reach and sight of children.

Disposal Requirements

Unused or expired Aciryl should be disposed of via a drug take-back program or an authorized mail-back program whenever available. If these options are not readily accessible, the FDA recommends discarding the medicine in the household trash only after: 1) removing it from its original container, 2) mixing it with an unappealing substance like dirt or used coffee grounds, and 3) sealing the mixture in a plastic bag or container. The medicine must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aciryl found in:

A-Z Index: